Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -287.22M | -310.96M | -308.55M | -296.38M | -239.24M |
Total Depreciation and Amortization | 7.96M | 7.63M | 7.31M | 7.00M | 6.83M |
Total Amortization of Deferred Charges | 2.64M | 2.39M | 2.34M | 2.61M | 2.57M |
Total Other Non-Cash Items | 114.31M | 143.85M | 120.88M | 119.61M | 113.14M |
Change in Net Operating Assets | 33.90M | 24.53M | 10.54M | -25.57M | -28.39M |
Cash from Operations | -128.41M | -132.57M | -167.49M | -192.73M | -145.08M |
Capital Expenditure | -270.00K | -247.00K | -528.00K | -609.00K | -582.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -270.00K | -247.00K | -528.00K | -609.00K | -582.00K |
Total Debt Issued | -- | 0.00 | 0.00 | 30.00M | 85.00M |
Total Debt Repaid | -990.00K | -660.00K | -349.00K | -163.00K | -- |
Issuance of Common Stock | 71.46M | 55.04M | 59.72M | 273.28M | 271.17M |
Repurchase of Common Stock | -3.95M | -3.70M | -3.58M | -2.59M | -1.84M |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -8.68M | -7.09M | -9.23M | -22.27M | -23.32M |
Cash from Financing | 57.84M | 43.59M | 46.56M | 278.26M | 331.01M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -70.84M | -89.22M | -121.46M | 84.93M | 185.35M |